Aymen I. Idris MSc. Ph.D.

Senior Lecturer, University of Sheffield.

E Mail - aymen.idris@sheffield.ac.uk

 

Previous Positions:

Lecturer in cancer associated bone disease, University of Edinburgh.

Postdoctoral Fellow, Universities of Edinburgh and Aberdeen.

PhD student, University of Aberdeen. 

 

 

 

   

 

 
     

 

 

 

     
     

 

 

   

 

 
     

 

Original Research Articles:

 

  • Sophocleous, A*, Marino S*, Logan J. G., Mollat P, Ralston S.H and Aymen I. Idris. Bone cell–autonomous contribution of type 2 cannabinoid receptor to breast cancer induced osteolysis. J. Bio Chem. 2015; 4:290(36): 22049-60. [PubMed]

*Authors contributed equally to manuscript.

 

  • Logan J. G., Sophocleous, A, Marino S, Muir M., Brunton V.G., and Aymen I. Idris. Selective tyrosine kinase inhibition of insulin-like growth factor-1 receptor inhibits human and mouse breast cancer induced bone cell activity, bone remodelling and osteolysis. J. Bone Miner. Res. 2014; 165:1914-25. [PubMed]

 

  • Frantzias J, Logan G.J, Mollat P, Sparatore A, Del Soldato P, Ralston S.H and Aymen I. Idris. Hydrogen sulfide releasing diclofenac derivatives inhibit breast cancer-induced osteoclastogenesis in vitro and prevent osteolysis ex vivo. Br J Pharmacol. 2012; 165(6), 1914. [PubMed]

 

  • Sophocleous A, Sims AH, Aymen I. Idris, Ralston SH. Genetic Background Modifies the Effects of Type 2 Cannabinoid Receptor Deficiency on Bone Mass and Bone Turnover. CTI. 2014. 94:259–268. [PubMed]

 

  • Sophocleous A and Aymen I. Idris. Rodent models of osteoporosis. IBMS BoneKEy. 2014; 10(3): 614, 1 - 9. [PubMed]

 

  • Sophocleous A, Aymen I. Idris, Ralston SH. Modulation of Strain-Specific Differences in Gene Expression by Cannabinoid Type 2 Receptor Deficiency. CTI. 2014. 94:423–432 [PubMed]

 

  • Aymen I. Idris and Stuart H. Ralston. Cannabinoids and bone: Friend or Foe?. CTI. 2010; 87(4):285-97. [PubMed]

d

  • Frantzias J, Logan G.J, Mollat P, Sparatore A, Del Soldato P, Ralston S.H and Aymen I. Idris. Hydrogen sulfide releasing diclofenac derivatives inhibit breast cancer-induced osteoclastogenesis in vitro and prevent osteolysis ex vivo. Br J Pharmacol. 2012. [PubMed]

 

  • Sophocleous A, Landao-Bassonga E, Van't Hof RJ, Aymen I. Idris, Ralston S.H. The Type 2 Cannabinoid Receptor Regulates Bone Mass and Ovariectomy-Induced Bone Loss by Affecting Osteoblast Differentiation and Bone Formation. Endocrinology. 2011. [PubMed]

 

  • Aymen I. Idris, Maala Krishnan, Petra Simic, Euphemie Landao-Bassonga, Patrick Mollat, Slobodan Vukicevic, and Ralston SH. Small molecule inhibitors of IKK signalling inhibit osteoclast formation in vitro and ovariectomy induced bone loss in vivo. FASEB J. 2010. [PubMed]

 

  • Aymen I. Idris. Cannabinoid receptors as target for treatment of osteoporosis: a tale of two therapies. Current Neuropharmacology. 2010; 8: 243-53. [PubMed]

 

  • Aymen I. Idris, E. Coste, I.R Greig, Ralston SH and R.J. van’t Hof. The orally active biphenyl carboxylic acid derivative ABD328 prevents ovariectomy bone loss in vivo. Calcif Tissue Int. 2010; [PubMed]

 

  • Aymen I. Idris and Stuart H. Ralston. Cannabinoids and bone: Friend or Foe? Calcif Tissue Int. 2010. [PubMed]

 

  • Aymen I. Idris, E. Landao-Bassonga and SH. Ralston. The TRPV1 receptor antagonist capsazepine inhibits osteoclast and osteoblast differentiation in vitro and ovariectomy induced bone loss in vivo. Bone. 2010; 46: 1089–1099. [PubMed]

 

  • Aymen I. Idris, Antonia Sophocleous, Euphemie Landao-Bassonga, Meritxell Canals, Graeme Milligan, David Baker, Robert vant Hof, Stuart Ralston. Cannabinoid receptor type 1 protects against age-related bone loss by regulating osteoblast and adipocyte differentiation of bone marrow stromal cells. Cell Metabolism. 2009; 10(2): 139 - 147. [PubMed]

 

  • Aymen I. Idris, Helene Libouban, Hervé Nyangoga, Euphemie Landao-Bassonga, Daniel Chappard and Stuart Ralston. Pharmacological inhibitors of IKK suppress growth and migration of mammary carcinosarcoma cells in vitro and prevent osteolytic bone metastasis in vivo. Molecular Cancer Therapeutics. 2009 8:2339-2347. [PubMed]

 

  • Aymen I. Idris, I.R Greig, S.H. Ralston and R.J. van’t Hof. Identification of Novel Biphenyl Carboxylic Acid Derivatives as Novel Antiresorptive Agents that Do Not Impair Parathyroid Hormone-Induced Bone Formation. Endocrinology. 2009; 150:5-13. [PubMed]

 

  • Sarah Aitken, Euphemie Landao-Bassonga, Stuart H. Ralston and Aymen I. Idris. Beta-2 adrenoreceptor ligands regulate osteoclast differentiation in vitro by direct and indirect mechanisms. Arch Biochem Biophys. 2009; 482:96-103. [PubMed]

 

  • Aymen I. Idris, Stuart H. Ralston and van’t Hof, RJ. The nitrosylated Flurbiprofen derivative HCT1026 inhibits bone resorption by suppressing RANKL signalling. Eur J Pharmacol. 2009 602 (2-3): 215-222. [PubMed]

 

  • Aymen I. Idris, Role of cannabinoid receptors in bone disorders: alternatives for treatment. Drug News Perspect. 2008; 21(10):533-40. [PubMed]
  • Aymen I. Idris, Antonia Sophocleous, Euphemie Landao-Bassonga, R.J. van’t Hof, S.H. Ralston. Role of the type 2 cannabinoid receptor CNR2 in regulating bone mass osteoclast function and ovariectomy-induced bone loss. Endocrinology. 2008; 149(11):5619–5626. [PubMed]

 

  • Aymen I. Idris, Emanuela Mrak, Iain Greig, Francesca Guidobonoc, Stuart H. Ralstona and Rob van’t Hof. ABD56 causes osteoclast apoptosis by inhibiting the NFκB and ERK pathways. Biochemical and Biophysical Research Communications. 2008; 371 (1): 94-98. [PubMed]

 

  • Aymen I. Idris, I.R Greig,  R.J. van’t Hof and S.H. Ralston. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro. Calcif Tissue Int. 2008; 82:191 – 201. [PubMed]

 

  • Alun Hughes, Michael J. Rogers, Aymen I. Idris and Julie C. Crockett. A Comparison between the Effects of Hydrophobic and Hydrophilic Statins on Osteoclast Function In Vitro and Ovariectomy-Induced Bone Loss In Vivo. Calcif Tissue Int. 2007; 81:403–413. [PubMed]

 

  • I.R Greig, Aymen I. Idris, S.H. Ralston and R.J. van’t Hof. Identification of biphenyl-carboxylic acid derivatives as a novel class of bone resorption inhibitors. J Med Chem. 2006; 14;49 (25):7487-7492. [PubMed]

 

  • Aymen I. Idris, R.J. van’t Hof, I.R Greig, S. Ridge, R. Ross, S.H. Ralston, R.J. van’t Hof. Cannabinoid receptor antagonists inhibit bone resorption and prevent ovariectomy induced bone loss. Nat Med. 2005; 11(6):1651-1660. [PubMed]

 

  • Aymen I. Idris*, R.J. van’t Hof*, I.R Greig, Susan A Ridge, James Dunford, S.H. Ralston. Identification of biphenyl-carboxylic acid derivatives as a novel class of bone resorption inhibitors. J Bone Miner Res. 2004;19:1651-1660. [PubMed]

*Authors contributed equally to manuscript.

 

  • Aymen I. Idris, R.J. van’t Hof, P. Del Soldato, S.H. Ralston. The NO-NSAID HCT1026 inhibits bone resorption by a novel mechanism independent of COX inhibition and nitric oxide production. Bone. 2004; 35:636-643. [PubMed]

Book Chapters:

 

  • Aymen I. Idris. Analysis of Signalling Pathways in Bone Cells. Bone Research Protocols. Totowa, NJ: Humana Press. 2012 [PubMed]

 

  • Aymen I. Idris. Ovariectomy and Orchidectomy in Rodents. Bone Research Protocols. Totowa, NJ: Humana Press. 2012. [PubMed]

  

Reviews:

 

  • Aymen I. Idris. The promise and dilemma of cannabinoid therapy: lessons from animal studies of bone disease. IBMS BoneKEy. 2011; 8(2): 84-95 [PubMed]

 

  • Sophocleous A and Aymen I. Idris. Rodent models of osteoporosis. IBMS BoneKEy. 2014; 10(3): 614, 1 - 9. [PubMed]

 

  • Aymen I. Idris. Cannabinoid receptors as target for treatment of osteoporosis: a tale of two therapies. Current Neuropharmacology. 2010; 8: 243-53. [PubMed].

 

  • Aymen I. Idris and Stuart H. Ralston. Cannabinoids and bone: Friend or Foe? Calcif Tissue Int. 2010. [PubMed]

  

  • Aymen I. Idris, Role of cannabinoid receptors in bone disorders: alternatives for treatment. Drug News Perspect. 2008; 21(10):533-40. [PubMed]

c

 

 

c

 

 

 

Cannabinoids and Bone:

Friend or Foe?

[PubMed]

 

 

Cannabinoids Receptors

& Bone Disorders

[PubMed]

CC